Lifemine Therapeutics Inc. has identified serine/threonine-protein phosphatase 2B (PPP3CC; PP2Bγ; calcineurin) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome (SARS), fungal infections, transplant rejection, and dermatological, respiratory and eye disorders.
Maplight Therapeutics Inc. has synthesized G protein-coupled receptor GPR6 inverse agonists reported to be useful for the treatment of anxiety, bipolar disorder, eating disorders, depression, schizophrenia, Huntington’s disease, Parkinson’s disease and Alzheimer’s disease, among others.
Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Etern Therapeutics (Wuxi) Co. Ltd. has divulged polycyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of ischemia-reperfusion injury.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
The Jackson Laboratory has disclosed short transient receptor potential channel 3 (TRPC3) and short transient receptor potential channel 6 (TRPC6) antagonists reported to be useful for the treatment of Alzheimer’s disease.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis, multiple sclerosis, pain, neuroinflammation, neurodegeneration, Alzheimer’s disease and inflammatory bowel disease, among other disorders.
RSS